The purpose of this study was to examine the disposition of diphenhydramine (DPHM) across the ovine blood-brain barrier (BBB). In six adult sheep, we characterized the central nervous system (CNS) pharmacokinetics of DPHM in brain extracellular fluid (ECF) and cerebrospinal fluid (CSF) using microdialysis in two experiments. In the first experiment, DPHM was administered via a five-step i.v. infusion (1.5, 5.5, 9.5, 13.5, and 17.5 g/kg/min; 7 h per step). Average steady-state CNS/total plasma concentration ratios (i.e., [ In the second experiment, DPHM was coadministered with propranolol (PRN) to examine its effect on blood-brain CSF and blood-brain ECF DPHM relationships. Plasma total DPHM concentration decreased by 12.8 ؎ 6.3% during PRN, whereas ECF and CSF concentrations increased (88.1 ؎ 45.4 and 91.6 ؎ 34.3%, respectively). This increase may be due to the inhibitory effect of PRN on a transporter-mediated efflux mechanism for DPHM brain elimination.
The blood-brain barrier (BBB) is composed of several specialized elements which act together to regulate the internal milieu of the brain (Smith, 1989; Farrell and Risau, 1994; Davson and Segal, 1996) by controlling the exchange of compounds between two barrier structures-one located between the blood and brain extracellular fluid (ECF), termed the blood/brain barrier, and the second between the blood and cerebrospinal fluid (CSF), known as blood/CSF barrier. Diphenhydramine [2-(diphenylmethoxy)-N,N-dimethylethylamine (DPHM)] is a potent histamine H 1 -receptor antagonist (Douglas, 1980) widely used for its antiallergic properties, as well as for its antiemetic, sedative, local anesthetic, and hypnotic effects (Runge et al., 1992; Ernst et al., 1993; Pontasch et al., 1993) . Like other "first-generation" antihistamines, DPHM occupies central H 1 -receptors to result in drowsiness, sedation, incoordination and with higher doses, convulsions, and death (Douglas, 1980; Nicholson, 1983; Koppel et al., 1987; Gengo et al., 1989) . However, there are limited data on the CNS levels of the drug or on the mechanisms of transfer involved. Results from previous studies in rats, guinea pigs, and rabbits suggest that DPHM enters the brain tissue and CSF extremely rapidly to achieve CNS concentrations exceeding those in plasma (Glazko and Dill, 1949a,b; Takasato et al., 1984; Goldberg et al., 1987) . Because only ϳ2.5% of DPHM (pK a ϳ9.0) is un-ionized at the physiological pH, the above results cannot be explained by the passive diffusion of this un-ionized form through the blood-brain and blood-CSF barriers. Moreover, there is evidence for saturable BBB transporter mechanisms for lipophilic, amine drugs (Pardridge et al., 1973 (Pardridge et al., , 1984 Spector, 1988; Yamazaki et al., 1994a,b,c) . This includes mepyramine, a histamine H 1 -antagonist. The available data suggest that these compounds cross the blood-brain and blood-CSF barriers by both simple diffusion of the un-ionized lipid-soluble form and by carrier-mediated transport of the ionized form (Pardridge et al., 1984; Goldberg et al., 1987; Yamazaki et al., 1994a) . In addition, there is evidence that various substances can inhibit the actions of this transport process. In vivo (rat carotid injection technique), brain uptake of mepyramine is inhibited by DPHM (Yamazaki et al., 1994a) . Further-more, both in vivo and in vitro (bovine brain capillary endothelial cells) studies demonstrate that propranolol (PRN) inhibits mepyramine uptake (Yamazaki et al., 1994; Yamazaki et al., 1994) . Together, these data led us to hypothesize that PRN could inhibit brain (and perhaps CSF) DPHM uptake. The purpose of our studies then was to use in vivo microdialysis (MD) in chronically instrumented adult ewes to investigate the transport processes of DPHM across the adult ovine blood-brain-barrier using two different experiments. The first involved stepped infusions of DPHM at five different dosing rates to assess blood-brain CSF and blood-brain ECF drug concentration relationships in relation to variations in drug dose and hence plasma drug levels. The second involved coadministration of DPHM and PRN to examine whether PRN alters blood-brain CSF and blood-brain ECF DPHM relationships.
Free-fraction drug concentration (C CSF or C ESF ) at the MD sampling site was equal to the diphenhydramine concentration in the output dialysate ([DPH-M] dialysate )/recovery rate.
Physiological Recording. Arterial pressure was measured using straingauge manometers (Ohmeda Inc., Madison, WI) and heart rates from a cardiotachometer (Astro-Med, West Warwick, RI). All variables were recorded on a Grass K2G polygraph (Astro-Med) and on a computerized data acquisition system (chart v4.2; ADInstruments, Grand Junction, CO).
Plasma Protein Binding of DPHM. Determination of plasma protein binding/unbound fraction (C Pu ) of DPHM was achieved using the equilibrium dialysis procedure described by Yoo et al. (1990) in the 7-h steady-state plasma sample from each infusion step of the five-step infusion studies. In the case of the DPHM-PRN coadministration study, a sample collected at 8 h of the infusion was used for measurement.
Drug Analysis. The concentrations of DPHM (C Pt , C Pu , C CSF , and C ECF ) in all samples were measured using a gas chromatographic-mass spectrometric assay capable of simultaneously measuring DPHM and [ 2 H 10 ]-DPHM with a limit of quantitation of 2.0 ng/ml (Tonn et al., 1993) .
Statistical and Data Analysis. All pharmacokinetic modeling was performed using WinNonlin, version 1.1 (Scientific Consulting Inc., Apex, NC).
Five-step infusion study. Volume of distribution (Vd) and total body clearance (Cl T ) were calculated using the following respective equations (Gibaldi and Perrier, 1982) :
where C Ptss is the plasma total steady-state DPHM concentration, and ␤ is the terminal elimination constant. Data were plotted using Microsoft Excel 2000 (Microsoft Corporation, Mountain View, CA). All data are reported as mean Ϯ S.D. Statistical analyses were performed using JMP IN, version 3.2.1 (SAS, Cary, NC). The significance level was p Ͻ 0.05 in all cases.
Calculation of f CSF and f ECF . The extent of DPHM transfer into the brain in this study was calculated by relating the CSF and ECF total area under the plasma concentration versus time curve (AUC 03ϱ ) values to the plasma AUC 03ϱ value to yield the f CSF and f ECF ratios. Specifically, using f CSF as an example:
The f ECF value was calculated in the same manner using total area under the ECF concentration versus time curve (AUC ECF 03ϱ ). This method of characterizing drug transfer across the BBB has been used in numerous other MD studies for many different drugs, including acetaminophen, atenolol, gabapentin, zidovudine, morphine-6-glucuronide, lamotrigine, phenobarbital, and felbamate (Wang et al., 1993; Wong et al., 1993; de Lange et al., 1994; Luer et al., 1999; Bouw et al., 2001; Potschka et al., 2002) . DPHM-PRN coadministration. Vd, Cl T , f CSF , and f ECF values in these experiments were estimated using the equations listed above. However, for comparisons of the DPHM alone and DPHM-PRN coadministration periods, DPHM concentrations and AUC values for the periods 0 to 4 h and 4 to 8 h, respectively, were used. Thus, to assess the effect of PRN on the f CSF value, for example, area under the CSF concentration versus time curve from 0 to 4 h (AUC 
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Five-
Step Infusion Study. Probe recovery rates ranged from 40 to 50% in all six animals, and the average values for the DPHM (46.1 Ϯ 3.3%) and DPHM-PRN (44.3 Ϯ 3.7%) experiments are not significantly different (Table 1 ). In addition, no significant differences in recovery rates were observed among the five infusion steps for both probes (ECF, 46.3 Ϯ 3.3%; CSF, 45.9 Ϯ 3.3%). The steady-state concentrations of DPHM in plasma, CSF, and ECF increased corre- Table 2 ). There was no significant difference between the steady-state CSF and ECF concentrations across the five steps. This similarity in the two CNS concentrations is especially evident upon examination of Fig. 1 . Due to the high level of plasma protein binding (86.1 Ϯ 2.3%), the plasma-free DPHM concentrations were lower than that in the CSF and ECF. This relationship is demonstrated clearly in Table 3 . The steady-state C CSF /C Pt and C ECF /C Pt ratios ranged from 0.4 to 0.5, whereas the C CSF /C Pu and C ECF /C Pu ratios ranged from 2 to 3. There was no significant difference between the C CSF /C Pt and C ECF /C Pt ratios and between the C CSF /C Pu and C ECF /C Pu ratios across the five steps. Figure 1 depicts the concentration-time relationships for the plasma, CSF, and ECF compartments for the five-step infusion study. All three concentrations increased in a linear manner corresponding to the increases in infusion rates. DPHM was present in the CSF and ECF within 15 min after starting the infusion, reaching 80 to 90% of the step 1 steady-state concentration.
The apparent distribution and elimination t 1/2 values of DPHM were obtained from a two-compartment model fitting of the postinfusion data using WinNonlin. Selection between a one-or twocompartment pharmacokinetic model was based upon the generation of lower Akaike Information Criterion values for a two-compartment fit of the data. All model fitting was carried out using a weighting factor of 1/predicted y 2 because it provides more accurate estimates at lower DPHM concentrations. The drug was extensively distributed in the animals, as shown by the high Vd value (27.9 Ϯ 17.4 l/kg) ( Table  6 ). Two-compartment pharmacokinetics were observed in the DPHM elimination profiles of all three fluids, with the CNS compartments FIG. 1. Plasma, CSF, and ECF DPHM concentrations achieved with the five-step infusion (loading doses, 0.15 mg/kg; and the infusion rates, 1.5, 5.5, 9.5, 13.5, and 17.5 g/kg/min). The duration of each infusion step was 7 h. Steady state was achieved in all fluids by 4 h. Error bars are omitted for clarity.
FIG. 2. Plasma, CSF, and ECF DPHM concentrations achieved with the DPHM-PRN coadministration study. DPHM was infused for 8 h at 13.5 g/kg/min, and propranolol was coinfused from 4 to 8 h at 20 g/kg/min. The ECF curve was based on results from three animals because of failure of ECF probes in three other animals. Both the plasma and CSF curves represent the results from six animals. Error bars are omitted for clarity. Data are shown as mean Ϯ S.D. n ϭ 6.
Infusion
Step
The C CSF /C Pt ratios were calculated by dividing the concentrations of the last sample of CSF with the last sample of plasma in each step. The same procedure was applied to the calculation of C ECF /C Pt ratios.
b The C CSF /C Pu ratios were calculated by dividing the concentration of the last sample of CSF with the free plasma concentration (determined by equilibrium dialysis) of the last plasma sample in each step. The same procedure was applied to the calculation of C ECF /C Pt ratios.
* Significantly different from the value of 1 (paired t test).
TABLE 1
Summary of microdialysis probe recovery rate in the five-step infusion and DPHM-PRN coadministration experiments
Data are shown as mean Ϯ S.D.
Step 1 Step 2 Step 3
Step 4 Step Figure 2 depicts the concentration-time relationships for the plasma, CSF, and ECF compartments from the DPHM-PRN coadministration study. Consistent with results from the five-step infusion study, elimination in all three fluids followed two-compartment pharmacokinetics (Table 6) . Tables 4 and 5 compare the DPHM concentrations in plasma, CSF, and ECF and C CSF and C ECF to C Pu ratios before and after propranolol coadministration. After PRN administration, C Pt tended to be lower, although this did not achieve statistical significance. However, the percentage decrease (12.8 Ϯ 6.3%) was significantly different from 0. In contrast, C ECF and C CSF concentrations increased during PRN administration, and for C CSF , the increase was statistically significant (Table 4) . For both C ECF and C CSF, the percentage increases (88.1 Ϯ 45.4% and 91.6 Ϯ 34.3%, respectively) were statistically significant. Similar to the five-step infusion study, the CNS concentrations were higher than the C Pu . As shown in Table 5 , the C CSF /C Pu and C ECF /C Pu ratios tended to increase during PRN infusion, but because of interanimal variability, the changes were not significant. However, the percentage increases in the ratios were significantly different. The protein binding value with propranolol coadministration was 84.4 Ϯ 10.5%, which was not significantly different from the value obtained in the five-step study (86.1 Ϯ 2.3%). Table 6 provides a summary comparing the pharmacokinetic parameters before and after PRN administration. Cl T tended to be higher with PRN coadministration, whereas Vd was lower, but these changes were not statistically significant. The elimination half-life in plasma tended to be lower during PRN and the half-life values in CSF and ECF higher, but none of these changes were statistically significant. The f ratios for both CSF and ECF were significantly increased.
Physiological Responses. In the five-step infusion study, during the administration of infusion steps 4 to 5, three animals showed symptoms of agitation including restlessness, tremor, excessive bleating, and heavy breathing. These symptoms disappeared 1 to 1.5 h after the end of the infusion. During steps 4 and 5, which involved the highest infusion rates, the mean arterial pressure (110 Ϯ 2.41 mm Hg for step 4 and 110 Ϯ 0.98 mm Hg for step 5) was not significantly different from the mean baseline value of 111 Ϯ 0.41 mm Hg. In terms of mean heart rate, no significant changes from baseline were observed during all five infusion steps.
In the DPHM-PRN study, no significant difference was observed in mean arterial pressure after PRN coinfusion (101 Ϯ 1.47 mm Hg) compared with DPHM administration alone (102 Ϯ 0.86 mm Hg). However, a significant drop in mean heart rate was observed with PRN coadministration (77.7 Ϯ 3.47 beats per minute) compared with DPHM alone (95.5 Ϯ 2.37 beats per minute), and this fall in heart rate persisted for the full 20-h duration of the experiment (Fig. 3 ).
Discussion
For both the blood-brain and blood-CSF barriers, the most important element is the tight junctions in the brain capillary endothelial cells and in the epithelial cells of the choroid plexus, respectively (Saunders et al., 1999) . The tight junctions primarily restrict the entry of proteins and other large hydrophilic molecules into the CNS (Davson and Segal, 1996; Habgood et al., 2000) . For lipophilic compounds not significantly bound to plasma proteins, there is a good correlation between the BBB permeability coefficient and the octanol/ water partition coefficient, provided the molecular mass is Ͻ400 to 600 Da (Levin, 1980) . However, numerous transporters are present in brain endothelial cells, which transfer substances into the CNS at rates higher than could occur via simple diffusion. There is also evidence for saturable transporter mechanisms in the BBB for a number of lipophilic amine drugs, including PRN and the histamine H 1 -antagonist mepyramine (Pardridge et al., 1984; Yamazaki et al., 1994b) . There are two possible paths for a substance from the CNS to return to the systemic circulation. One is efflux (transporter-mediated or not) via brain or choroidal blood. The second route involves efflux via bulk flow of CSF draining into either the lymphatic system or venous blood (Bradbury et al., 1972) . The latter phenomenon is termed the sink effect, whereby the brain concentrations of different compounds under steady-state conditions are different from each other and lower than the unbound concentration in blood (Davson and Segal, 1996) , as a consequence of the continuous removal of the substances via the CSF.
In this study, we applied the microdialysis technique to investigate the blood-brain CSF and blood-brain ECF DPHM relationships in two different experiments. In the first experiment, the results from the five-step infusion showed that brain concentrations increased correspondingly to increases in dose, suggesting that the transfer of DPHM # a Pre-PRN concentrations were determined from samples taken at 4 h (immediately before PRN administration) of the DPHM infusion. b DPHM ϩ PRN concentrations were determined from samples taken at 8 h of the coadministration study (i.e. 4 h after PRN was coinfused). c Free-fraction plasma concentrations were determined by performing equilibrium dialysis on the corresponding plasma samples. d n ϭ 3 for C ECF because of failure of ECF probes in three of the animals. Otherwise, n ϭ 6 for C Pt , C Pu , and C CSF . e Percent change in DPHM concentrations after PRN coadministration, with respect to that from DPHM administration alone. * Significantly different from the pre-PRN value (paired t test). # Significantly different from 0 (paired t test).
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at ASPET Journals on April 6, 2017 dmd.aspetjournals.org into the CNS was a concentration-dependent process. However, considering the high degree of plasma protein binding (86.1 Ϯ 2.3%), the CNS DPHM concentrations were actually higher than the free DPHM concentration in plasma (Tables 2-5 ). This suggested that the entry of DPHM into the CNS was most likely due to an active transport process, because if passive diffusion was the only driving force, then free plasma DPHM concentrations should be comparable with the CNS levels. In fact, our findings indicated that DPHM concentrations were at least 2 times higher than free plasma concentrations (Table 3) . As mentioned earlier, there are data suggesting that lipophilic, amine compounds such as DPHM can cross the blood-brain and blood-CSF barriers by both simple diffusion of the un-ionized lipid-soluble form and by carrier-mediated transport of the ionized form (Pardridge et al., 1984; Goldberg et al., 1987; Yamazaki et al., 1994a) . The postulation of an active transport process is supported by the C CSF /C Pu and C ECF /C Pu ratios, both ranging from 2 to 3 (Table 3) . Transfer of DPHM into the CNS was rapid after administration; this was not a surprising observation considering the highly lipophilic nature of this compound [octanol/water partition coefficient 1862 (Douglas, 1980) ]. Other reports also suggest rapid distribution of DPHM into tissues, with the maximum tissue uptake occurring at 1 to 3 min after i.v. injection (Drach et al., 1970) . The close similarities between the two CNS drug concentrations (Table 2 and Fig. 1 ) suggest that drug clearances in the choroid plexus and the cerebral cortex are comparable with each other. This observation can further be assessed by comparing the f CSF and f ECF values (0.4 Ϯ 0.2 and 0.4 Ϯ 0.2, respectively), which were not significantly different from each other. Two-compartment pharmacokinetics were observed in the DPHM elimination profiles of all three fluids in the five-step infusion studies, with the CNS compartments declining at the highest rates (Table 6 ). This was reflected in the half-life (t 1/2␤plasma , 10.8 Ϯ 5.4 versus t 1/2␤CSF , 3.6 Ϯ 1.0; t 1/2␤ECF , 5.3 Ϯ 4.2 h) values. The more rapid elimination of DPHM from the brain compared plasma is associated with higher concentrations of the drug in the CNS compared with the unbound plasma concentration (Table 2) . This is probably due to active transport of the ionized DPHM into the brain, as discussed previously, so that more of the total circulating concentration of the drug is available to the brain compared with other organs and tissues.
The rapid efflux of DPHM from CNS could be due to the bulk flow of CSF (sink effect) and also involvement of a transporter-mediated efflux mechanism for the drug. The validity of the above assumption can be assessed by examining the results from the DPHM-PRN experiment. The CSF DPHM concentration increased significantly during PRN coadministration and for both CSF and ECF the percentage increase in drug levels was statistically significant (Table 4 ). In addition, both the f CSF and f ECF increased after the coadministration of propranolol (from 0.40 Ϯ 0.20 and 0.40 Ϯ 0.20 to 0.69 Ϯ 0.03 and 0.95 Ϯ 0.05, respectively), with f ECF being significantly increased. The trend for an increase in the CSF and ECF DPHM elimination half-life after PRN is also consistent with reduced clearance of the drug from the brain. However, these changes were not statistically significant. Although the PRN infusion was not continued into the elimination phase, the persistence of the PRN-elicited bradycardia for the entire duration of the experiment (Fig. 3) indicates that there was sufficient PRN still present during the elimination period for this action and thus perhaps also for an effect on DPHM transfer across the BBB. Overall, the findings suggest lower DPHM clearances from the CNS after PRN coadministration.
As mentioned earlier, besides the bulk flow of CSF, efflux of substances (transporter-mediated or not) can occur via brain or choroidal blood back to the systemic circulation. To date, there is no information showing that PRN lowers CSF formation or its secretion rates and that it has any interference with the passive diffusion process of substances back to the cerebral circulation. In addition, besides a slight decrease in heart rate, PRN causes no systemic or cerebral physiologic changes in sheep (O'Brien et al., 1999) . In another study, PRN infusion did not significantly change choroid plexus blood flow in sheep (Townsend et al., 1984) . Results from these studies are consistent with our current findings in that only heart rate, but not arterial pressure, was affected by PRN. Therefore, the lowered brain clearances are probably due to lowered rates of efflux of the drug. FIG. 3. Heart rate versus time in the DPHM-PRN coadministration study (n ϭ 6). The arrow denotes the start of the PRN infusion. The asterisk denotes a significant decrease from pre-PRN heart rate (p Ͻ 0.05). Error bars are omitted for clarity.
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Propranolol can be involved in this process in one or both of the following manners-by directly inhibiting the efflux mechanism and/or by competing with DPHM for the efflux process. Both of these actions could be responsible for the observed lowered rates of CNS clearances; however, the exact mechanism cannot be elucidated by our current experiments. In contrast to the situation with DPHM concentrations in CSF and ECF, the plasma total DPHM level fell by 12.8% during PRN coadministration. This may have been due to an increase in systemic clearance of the drug, given the trend for an increase in this variable during PRN and for a decrease in t 1/2␤ (Table 6 ). DPHM has a high hepatic extraction in sheep, and thus its hepatic clearance is largely dependent on hepatic blood flow (Kumar et al., 1999) . However, PRN has been reported to decrease hepatic blood flow in humans (Zoller et al., 1993; Orszulak-Michalak, 1995) ; thus, the mechanisms involved in the decreased plasma DPHM concentration are unclear.
In summary, using in vivo microdialysis in chronically instrumented adult ewes, we have demonstrated that DPHM enters the brain rapidly after administration by passive diffusion and an active transfer process. Drug concentrations are markedly higher in the brain relative to unbound plasma levels and this may, in part, explain the significant CNS effects of the drug. DPHM clearances from brain ECF and CSF were similar and faster than plasma clearance, as indicated by the relatively short half-lives in the brain. The rapid efflux of DPHM from the CNS could be due to the bulk flow of CSF (sink effect) and also a transport-mediated efflux mechanism for the drug. The DPHM-PRN coadministration study suggests that PRN inhibits an efflux rather than influx mechanism. This latter finding was rather unexpected and warrants further investigation.
